[Comment] Endpoint selection in HER2-positive early breast cancer

Leggi l'articolo originale


Compared with definitive endpoints such as overall survival, the use of intermediate endpoints such as disease-free survival improves the efficiency of trial design, resulting in studies requiring smaller sample sizes and shorter follow-up. In oncology, the validation of intermediate endpoints as adequate surrogates of definitive outcomes is challenging.1 In early-stage breast cancer, evidence supporting the surrogacy of intermediate endpoints and definitive outcomes such as overall survival is scarce.

Lascia un commento